Novanta Inc (NOVT) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Novanta Inc (NOVT) has a cash flow conversion efficiency ratio of 0.038x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($50.31 Million) by net assets ($1.31 Billion). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See debt-free asset ratio of Novanta Inc to measure how much of total assets are equity-financed.
Novanta Inc - Cash Flow Conversion Efficiency Trend (1998–2025)
This chart illustrates how Novanta Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check Novanta Inc cash flow quality index to evaluate the quality of earnings relative to operating cash generation.
Novanta Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Novanta Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Hubei Xingfa Chemicals Group Co Ltd
SHG:600141
|
0.021x |
|
Versant Media Group, Inc.
NASDAQ:VSNT
|
0.046x |
|
Zhongfu Shenying Carbon Fiber Co. Ltd. A
SHG:688295
|
N/A |
|
UNIQA Insurance Group AG
VI:UQA
|
0.072x |
|
Selective Insurance Group, Inc.
NASDAQ:SIGI
|
0.062x |
|
Sichuan Em Technology Co Ltd
SHG:601208
|
-0.017x |
|
CONVATEC GRP UNSP.ADR /4
F:2CVU
|
N/A |
|
Greek Organization of Football Prognostics S.A.
AT:OPAP
|
0.457x |
Annual Cash Flow Conversion Efficiency for Novanta Inc (1998–2025)
The table below shows the annual cash flow conversion efficiency of Novanta Inc from 1998 to 2025. For the full company profile with market capitalisation and key ratios, see Novanta Inc (NOVT) market capitalisation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $1.31 Billion | $64.06 Million | 0.049x | -77.07% |
| 2024-12-31 | $745.70 Million | $158.51 Million | 0.213x | +19.22% |
| 2023-12-31 | $673.46 Million | $120.08 Million | 0.178x | +13.44% |
| 2022-12-31 | $577.59 Million | $90.78 Million | 0.157x | -13.41% |
| 2021-12-31 | $521.29 Million | $94.62 Million | 0.182x | -38.28% |
| 2020-12-31 | $476.81 Million | $140.24 Million | 0.294x | +94.00% |
| 2019-12-31 | $417.17 Million | $63.25 Million | 0.152x | -37.72% |
| 2018-12-31 | $368.25 Million | $89.65 Million | 0.243x | +37.69% |
| 2017-12-31 | $358.47 Million | $63.38 Million | 0.177x | -4.23% |
| 2016-12-31 | $258.87 Million | $47.79 Million | 0.185x | +35.18% |
| 2015-12-31 | $244.70 Million | $33.42 Million | 0.137x | -31.78% |
| 2014-12-31 | $211.25 Million | $42.29 Million | 0.200x | -1.37% |
| 2013-12-31 | $242.40 Million | $49.20 Million | 0.203x | +62.92% |
| 2012-12-31 | $228.21 Million | $28.43 Million | 0.125x | -42.26% |
| 2011-12-31 | $209.36 Million | $45.17 Million | 0.216x | +469.40% |
| 2010-12-31 | $81.12 Million | $-4.74 Million | -0.058x | -122.96% |
| 2009-12-31 | $152.90 Million | $38.90 Million | 0.254x | 0.00% |
| 2008-12-31 | $152.90 Million | $38.90 Million | 0.254x | +88.84% |
| 2007-12-31 | $278.24 Million | $37.49 Million | 0.135x | +31.11% |
| 2006-12-31 | $343.07 Million | $35.26 Million | 0.103x | +547.68% |
| 2005-12-31 | $306.56 Million | $4.86 Million | 0.016x | -86.30% |
| 2004-12-31 | $305.56 Million | $35.40 Million | 0.116x | +38.41% |
| 2003-12-31 | $260.79 Million | $21.83 Million | 0.084x | +81.78% |
| 2002-12-31 | $254.48 Million | $11.72 Million | 0.046x | +174.37% |
| 2001-12-31 | $282.33 Million | $-17.48 Million | -0.062x | -75.22% |
| 2000-12-31 | $289.27 Million | $-10.22 Million | -0.035x | -37.87% |
| 1999-12-31 | $171.70 Million | $-4.40 Million | -0.026x | +55.74% |
| 1998-12-31 | $120.90 Million | $-7.00 Million | -0.058x | -- |
About Novanta Inc
Novanta Inc., together with its subsidiaries, provides precision medicine, precision manufacturing, medical solutions, robotics and automation solutions, and advanced surgery solutions in the United States and internationally. The company operates Automation Enabling Technologies and Medical Solutions segments. The Precision Medicine and Manufacturing segment designs, manufactures, and markets la… Read more